Kaidi Guo1,2, Li Li1,2. 1. Department of Gynecology and Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, People's Republic of China. 2. Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Ministry of Education, Nanning, Guangxi, People's Republic of China.
Abstract
PURPOSE: Ovarian cancer is one of the common malignant tumors of female reproductive organs, which seriously threatens the life and health of women. Resistance to chemotherapeutic drugs for ovarian cancer is the root cause of recurrence in most patients. The purpose of this study is to determine the differentially expressed genes of platinum resistance in ovarian cancer, and to screen out molecular targets and diagnostic markers that could be used to treat ovarian cancer platinum resistance. METHODS: We downloaded 5 gene microarray datasets GSE58470, GSE45553, GSE41499, GSE33482, and GSE15372 from the Gene Expression Omnibus database, all of which are associated with ovarian cancer platinum resistance. Subsequently, the intersection of the statistically significant differentially expressed genes in 5 gene chips was taken, and relevant bioinformatics and clinical parameters were performed on the screened differential genes. qRT-PCR was utilized to examine the mRNA expression levels in ovarian cancer sensitive and cisplatin-resistant cells. RESULTS: Three differential genes, IFI27, JAG1, DNM3, may be closely related to platinum resistance of ovarian cancer, were screened by microarray datasets. According to the combined verification of bioinformatics, clinical case analyses and experiments, it was inferred that the increased expression of DNM3 was beneficial to patients with platinum resistance, but the high expression of IFI27 and JAG1 may lead to the risk of platinum resistance. CONCLUSION: IFI27, JAG1 and DNM3 screened by relevant gene chips may serve as new biomarkers of platinum resistance in ovarian cancer.
PURPOSE: Ovarian cancer is one of the common malignant tumors of female reproductive organs, which seriously threatens the life and health of women. Resistance to chemotherapeutic drugs for ovarian cancer is the root cause of recurrence in most patients. The purpose of this study is to determine the differentially expressed genes of platinum resistance in ovarian cancer, and to screen out molecular targets and diagnostic markers that could be used to treat ovarian cancer platinum resistance. METHODS: We downloaded 5 gene microarray datasets GSE58470, GSE45553, GSE41499, GSE33482, and GSE15372 from the Gene Expression Omnibus database, all of which are associated with ovarian cancer platinum resistance. Subsequently, the intersection of the statistically significant differentially expressed genes in 5 gene chips was taken, and relevant bioinformatics and clinical parameters were performed on the screened differential genes. qRT-PCR was utilized to examine the mRNA expression levels in ovarian cancer sensitive and cisplatin-resistant cells. RESULTS: Three differential genes, IFI27, JAG1, DNM3, may be closely related to platinum resistance of ovarian cancer, were screened by microarray datasets. According to the combined verification of bioinformatics, clinical case analyses and experiments, it was inferred that the increased expression of DNM3 was beneficial to patients with platinum resistance, but the high expression of IFI27 and JAG1 may lead to the risk of platinum resistance. CONCLUSION: IFI27, JAG1 and DNM3 screened by relevant gene chips may serve as new biomarkers of platinum resistance in ovarian cancer.
Authors: Jo-Anna Reems; Wenjing Wang; Ken Tsubata; Najla Abdurrahman; Birgitta Sundell; Marloes R Tijssen; Ellen van der Schoot; Franca Di Summa; Sunita Patel-Hett; Joseph Italiano; Diana M Gilligan Journal: Exp Hematol Date: 2008-12 Impact factor: 3.084
Authors: Justyna Mikuła-Pietrasik; Anna Witucka; Martyna Pakuła; Paweł Uruski; Beata Begier-Krasińska; Arkadiusz Niklas; Andrzej Tykarski; Krzysztof Książek Journal: Cell Mol Life Sci Date: 2018-10-31 Impact factor: 9.261
Authors: Mayte Guadalupe Cervantes-Badillo; Alejandro Paredes-Villa; Vania Gómez-Romero; Rafael Cervantes-Roldán; Luis E Arias-Romero; Olga Villamar-Cruz; Miroslava González-Montiel; Tonatiuh Barrios-García; Alberto J Cabrera-Quintero; Gabriel Rodríguez-Gómez; Laura Cancino-Villeda; Alejandro Zentella-Dehesa; Alfonso León-Del-Río Journal: Front Endocrinol (Lausanne) Date: 2020-10-07 Impact factor: 5.555